Proglumide potentiates morphine analgesia for acute postsurgical pain

Gilles J. Lavigne, Kenneth M. Hargreaves, Elizabeth A. Schmidt, Raymond A. Dionne

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Proglumide, an antagonist of cholecystokinin, has been shown to potentiate morphine analgesia in animal and human experimental pain models. This study was undertaken to determine whether proglumide enhances morphine analgesia for patients experiencing postoperative pain. At onset of pain after the removal of impacted third molars, patients (n = 60) received intravenously either 4 mg morphine, 8 mg morphine, or 4 mg morphine plus proglumide (0.05, 0.5, or 5 mg). The administration of 8 mg morphine significantly reduced pain, in comparison with baseline and 4 mg morphine, for the first 30 minutes. The addition of 0.05 mg proglumide resulted in a significant increase in the magnitude and duration of the analgesic activity of 4 mg morphine; 0.5 and 5.0 mg proglumide did not produce this effect. No difference was seen in respiratory rate or in the frequency of side effects among the various forms of treatment. These data indicate that a low dose of proglumide potentiates both the magnitude and the duration of morphine analgesia in a clinical model of acute pain, without any detectable increase in side effects.

Original languageEnglish (US)
Pages (from-to)666-673
Number of pages8
JournalClinical Pharmacology and Therapeutics
Issue number6
StatePublished - Jun 1989
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Proglumide potentiates morphine analgesia for acute postsurgical pain'. Together they form a unique fingerprint.

Cite this